Publications

Selected Publications (Ishizuka Lab)

1. Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma.

Griffin GK, Weirather JL, Roemer M, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Gjini E, Chapuy B, Rosenthal M, Xu J, Chen BJ, Sohani A, Lovitch SB, Abramson J, Ishizuka JJ, Kim AI, Jacobson CA, LaCasce AS, Fletcher CDM, Neuberg D, Freeman GJ, Hodi FS, Wright K, Ligon AH, Jacobsen ED, Armand P, Shipp MA, Rodig SJ.

Blood. 2020 Sep 1:blood.2020006464. doi: 10.1182/blood.2020006464. Online ahead of print.

2. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.

Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Cancer. 2020 Aug 15;126(16):3758-3767. doi: 10.1002/cncr.32966. Epub 2020 Jun 22.

3. Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.

Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Nat Immunol. 2019 Nov;20(11):1556. doi: 10.1038/s41590-019-0528-5.

4. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.

Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. J Clin Oncol. 2019 Oct 20;37(30):2786-2794. doi: 10.1200/JCO.19.01021. Epub 2019 Aug 28.

5. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.

6. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.

Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN. Nature. 2019 Jan;565(7737):43-48. doi: 10.1038/s41586-018-0768-9. Epub 2018 Dec 17.

7. Quantitating T cell cross-reactivity for unrelated peptide antigens.

Ishizuka J, Grebe K, Shenderov E, Peters B, Chen Q, Peng Y, Wang L, Dong T, Pasquetto V, Oseroff C, Sidney J, Hickman H, Cerundolo V, Sette A, Bennink JR, McMichael A, Yewdell JW. J Immunol. 2009 Oct 1;183(7):4337-45. doi: 10.4049/jimmunol.0901607. Epub 2009 Sep 4.

8. The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain.

Ishizuka J, Stewart-Jones GB, van der Merwe A, Bell JI, McMichael AJ, Jones EY.

Immunity. 2008 Feb;28(2):171-82. doi: 10.1016/j.immuni.2007.12.018.

Selected Publications (Wilson Lab)

1. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. The Lancet. Oncology 2020, 21:655-663.

2. Larotrectinib in NTRK-Rearranged Solid Tumors

Wilson FH, Herbst RS. Biochemistry 2019, 58:1555-1557.

3. ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation.

Wilson FH, Politi K.

Cancer Discovery 2018, 8:676-678.

4. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova E, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Janne PA.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24:5963-5976.

5. Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets.

Stewart T, Finberg K, Walther Z, Sklar JL, Hafez N, Eder JP, Anderson K, Wilson F, Goldberg SB.

The Lancet. Oncology 2018, 19:1567-1568.

6. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study.

Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, Corsello SM, Nguyen T, Rana HQ, Church AJ, Lowenstein C, Cibulskis C, Amin-Mansour A, Heng J, Brais L, Santos A, Bauer P, Waldron A, Lo P, Gorman M, Lydon CA, Welch M, McNamara P, Gabriel S, Sholl LM, Lindeman NI, Garber JE, Joffe S, Van Allen EM, Gray SW, Ja Nne PA, Garraway LA, Wagle N. Official Journal Of The American College Of Medical Genetics 2017, 19:787-795.

7. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.

Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F, Weir BA, Fitzgerald ME, Tanaka M, Bielski CM, Scott JM, Dennis C, Cowley GS, Boehm JS, Root DE, Golub TR, Clish CB, Bradner JE, Hahn WC, Garraway LA. Science (New York, N.Y.) 2016, 351:1214-8.

8. A functional landscape of resistance to ALK inhibition in lung cancer.

Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, Meyerson M, Root DE, Jänne PA, Garraway LA. Cancer Cell 2015, 27:397-408.

9. Genetic modifiers of EGFR dependence in non-small cell lung cancer.

Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M.

Proceedings Of The National Academy Of Sciences Of The United States Of America 2014, 111:18661-6.

Selected Publications (Müschen Lab)

1. PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis.

Pan L, Hong C, Chan LN, Xiao G, Malvi P, Robinson ME, Geng H, Reddy ST, Lee J, Khairnar V, Cosgun KN, Xu L, Kume K, Sadras T, Wang S, Wajapeyee N, Müschen M.

Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):e2016553118. doi: 10.1073/pnas.2016553118.

2. Metabolic Gatekeepers of Pathological B Cell Activation.

Sadras T, Chan LN, Xiao G, Müschen M.

Annu Rev Pathol. 2021 Jan 24;16:323-349. doi: 10.1146/annurev-pathol-061020-050135. Epub 2020 Dec 15.

3. IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.

Lee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, Nix MA, Klemm L, Chen CW, Chen J, Khairnar V, Wiita AP, Thomas-Tikhonenko A, Farzan M, Jung JU, Weinstock DM, Manalis SR, Diamond MS, Vaidehi N, Müschen M.

Nature. 2020 Dec;588(7838):491-497. doi: 10.1038/s41586-020-2884-6. Epub 2020 Nov 4.

4. Signalling input from divergent pathways subverts B cell transformation.

Chan LN, Murakami MA, Robinson ME, Caeser R, Sadras T, Lee J, Cosgun KN, Kume K, Khairnar V, Xiao G, Ahmed MA, Aghania E, Deb G, Hurtz C, Shojaee S, Hong C, Pölönen P, Nix MA, Chen Z, Chen CW, Chen J, Vogt A, Heinäniemi M, Lohi O, Wiita AP, Izraeli S, Geng H, Weinstock DM, Müschen M.

Nature. 2020 Jul;583(7818):845-851. doi: 10.1038/s41586-020-2513-4. Epub 2020 Jul 22.

5. Origins of the human B-cell lineage.

Müschen M.

Blood. 2019 Sep 26;134(13):998-999. doi: 10.1182/blood.2019002573.

6. Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia.

Hurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Chen CW, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M.

Genes Dev. 2019 Sep 1;33(17-18):1265-1279. doi: 10.1101/gad.327593.119. Epub 2019 Aug 8.

7. Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation.

Müschen M.

Nat Rev Immunol. 2019 May;19(5):337-348. doi: 10.1038/s41577-019-0154-3.

8. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.

Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M.

Cell. 2018 Apr 5;173(2):470-484.e18. doi: 10.1016/j.cell.2018.02.048. Epub 2018 Mar 15.

9. Autoimmunity checkpoints as therapeutic targets in B cell malignancies.

Müschen M.

Nat Rev Cancer. 2018 Feb;18(2):103-116. doi: 10.1038/nrc.2017.111. Epub 2018 Jan 5.

10. B-cell identity as a metabolic barrier against malignant transformation.

Chan LN, Müschen M.

Exp Hematol. 2017 Sep;53:1-6. doi: 10.1016/j.exphem.2017.06.004. Epub 2017 Jun 24.

11. Metabolic gatekeeper function of B-lymphoid transcription factors.

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M.

Nature. 2017 Feb 23;542(7642):479-483. doi: 10.1038/nature21076. Epub 2017 Feb 13.